Table 1.
Cannabinoid products with approved indications
| Drug | Name | Indication | Date of First Approval |
|---|---|---|---|
| Nabilone | Cesamet | Refractory nausea and vomiting associated with cancer chemotherapy | 1985 |
| Dronabinol | Marinol, Syndros, | Anorexia associated with weight loss in patients with AIDS; refractory nausea and vomiting associated with cancer chemotherapy | 1985 |
| Cannabis extract (includes both THC and CBD) | Sativexa | Refractory spasticity due to multiple sclerosis | 2010 |
| CBD | Epidiolex | Seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex | 2018 |
These products have been approved for the indications listed in the United States and/or Canada, and by the European Medicines Agency. THC, tetrahydrocannabinol; CBD, cannabidiol.
a
Not approved by the Food and Drug Adminstration.